GPER1 and neoplasm: The divergent results reported by the various immunohistochemical investigations may in part be due to the wide variety of polyclonal antibodies used across studies, which were derived from different commercial and non-commercial sources; however, some differences may also be associated with variations in the signalling pathways utilised by GPER in different tumour types (and potentially in different tumour subtypes) [1,15].